scholarly journals S10 The Impact of Omalizumab on Lung Function and Quality of Life in Patients with Severe Allergic Asthma in UK Clinical Practice: A multi-centre prospective observational study – APEX II

Thorax ◽  
2015 ◽  
Vol 70 (Suppl 3) ◽  
pp. A9.2-A10
Author(s):  
R Niven ◽  
R Kurukulaaratchy ◽  
L Heaney
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Lung Function ◽  
Observational Study ◽  
Allergic Asthma ◽  
Prospective Observational Study ◽  
Severe Allergic Asthma ◽  
The Impact

scholarly journals Clinical, radiological and functional outcomes in patients with SARS-CoV-2 pneumonia: a prospective observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Pietro Gianella ◽  
Elia Rigamonti ◽  
Marco Marando ◽  
Adriana Tamburello ◽  
Lorenzo Grazioli Gauthier ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Observational Study ◽  
Ct Scan ◽  
Prospective Observational Study ◽  
Lung Function Tests ◽  
Medium Term ◽  
Function Tests

Abstract Background All over the world, SARS-CoV-2 pneumonia is causing a significant short-term morbidity and mortality, but the medium-term impact on lung function and quality of life of affected patients are still unknown. Methods In this prospective observational study, 39 patients with SARS-CoV-2 pneumonia were recruited from a single COVID-19 hospital in Southern Switzerland. At three months patients underwent radiological and functional follow-up through CT scan, lung function tests, and 6 min walking test. Furthermore, quality of life was assessed through self-reported questionnaires. Results Among 39 patients with SARS-CoV-2 pneumonia, 32 (82% of all participants) presented abnormalities in CT scan and 25 (64.1%) had lung function tests impairment at three months. Moreover, 31 patients (79.5%) reported a perception of poor health due to respiratory symptoms and all 39 patients showed an overall decreased quality of life. Conclusions Medium-term follow up at three months of patients diagnosed with SARS-CoV-2 pneumonia shows the persistence of abnormalities in CT scans, a significant functional impairment assessed by lung function tests and a decreased quality of life in affected patients. Further studies evaluating the long-term impact are warranted to guarantee an appropriate follow-up to patients recovering from SARS-CoV-2 pneumonia.

scholarly journals P.045 Quality of life and treatment satisfaction in onabotulinumtoxinA-treated cervical dystonia patients: multicentre, prospective, observational study, posture

2016 ◽  
Vol 43 (S2) ◽  
pp. S32-S32
Author(s):  
M Petitclerc ◽  
M Bhogal ◽  
S Dhani ◽  
L Belle Blagrove
Keyword(s):  
Quality Of Life ◽  
Observational Study ◽  
Cervical Dystonia ◽  
Treatment Satisfaction ◽  
Prospective Observational Study ◽  
Rating Scale ◽  
Numeric Rating Scale ◽  
Post Treatment ◽  
The Impact

Background: Health-related quality of life (HRQoL) data is valuable, but limited. This analysis describes the impact of onabotulinumtoxinA treatment on HRQoL and level of treatment satisfaction in cervical dystonia (CD) patients. Methods: A multicenter, prospective, observational study in CD patients initiating onabotulinumtoxinA treatment (NCT01655862); ≤8 treatments administered at the physician’s discretion. Primary measures (baseline, 4/8 weeks post-treatment, and before final treatment): pain numeric rating scale (PNRS) and cervical dystonia impact profile questionnaire (CDIP-58). Secondary measures (8 weeks post-treatment): patient/physician treatment satisfaction. Results: 61 patients (31.3-86.3 years old) were enrolled (efficacy cohort); majority had moderately severe CD (77.0%) and were female (77%). CDIP-58 domain and PNRS scores decreased from baseline, with significant changes (p<.0001) by 4 weeks post-treatment 3 (mean±SD): symptoms (-18.8±16.1), daily activities (-7.2±13.7), psychosocial sequelae (-17.4±13.4), and PNRS (-1.8±3.3). Most patients (78.0% and 94.4%) felt their condition was improved and majority of physicians (68.9% and 75.0%) indicated satisfaction with patients’ responses following treatments 1 and 2, respectively. 27 patients reported 56 treatment-related adverse events (52 resolved, 4 ongoing); none were serious. Conclusions: No new safety signals were identified. Patients and physicians appear to be satisfied with onabotulinumtoxinA treatment for CD. Results suggest that onabotulinumtoxinA treatment may help improve HRQoL.

scholarly journals Evaluation of drug utilization pattern, quality of life and pharmaco-economics in patients of contact dermatitis: a prospective observational study

2021 ◽  
Vol 8 (1) ◽  
pp. 39
Author(s):  
Jolly M. Harkhani ◽  
Ashish Jagati ◽  
Hemant Tiwari ◽  
Shikha V. Sood ◽  
Supriya D. Malhotra
Keyword(s):  
Quality Of Life ◽  
Contact Dermatitis ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Tertiary Care ◽  
Health Care Facilities ◽  
Average Score ◽  
Total Cost ◽  
The Impact

<p class="abstract"><strong>Background: </strong>Contact dermatitis (CD) is a common inflammatory skin condition due to T-cell mediated immune reaction on exposure to different allergens. The disease significantly affects Quality of Life (QoL) and all over impact can be seen in Pharmacoeconomics.</p><p class="abstract"><strong>Methods: </strong>This is the prospective observational study done between October 2019 to February 2020 at Dermatology outpatient department (OPD) of a tertiary care teaching hospital. Patients diagnosed with CD aged eighteen years or older of either gender and willing to give written consent were included in study. The impact of CD on the QoL of affected persons was assessed using the Dermatology Life Quality Index (DLQI). Direct, indirect and total cost as well as percentage variation in cost of individual drugs was calculated for Pharmacoeconomics analysis.</p><p class="abstract"><strong>Results:</strong> The study population consisted of 180 patients. The most commonly prescribed drugs were corticosteroids (47.44%). The average score of DLQI at baseline was 8.97±4.85. The DLQI score was significantly more impaired in women as compared to men (12.91versus 4.93) (p=0.0001). Average income per month was 11,611.11±230.34₹. The average direct, indirect and total cost was 131.55±70.55 ₹, 136.44±16.93 ₹ and 168.11±74.08₹ respectively. The percentage variation of cost was largest for prednisolone 5 mg tablet and least for clobetasol cream (0.05%).</p><p class="abstract"><strong>Conclusions: </strong>The impact of CD on QoL and Pharmacoeconomic burden is significant and requires specific attention in health care facilities.  </p>

Sign in / Sign up

Export Citation Format

Share Document